Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):745-58. doi: 10.1517/17425255.2012.686603. Epub 2012 May 16. Review.

PMID:
22587686
2.

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS.

Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330. Epub 2013 May 29. Review.

3.

Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.

Ramadan WH, Kabbara WK.

Vasc Health Risk Manag. 2015 Feb 11;11:125-32. doi: 10.2147/VHRM.S79198. eCollection 2015. Review.

4.

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Scheen AJ.

Clin Pharmacokinet. 2010 Sep;49(9):573-88. doi: 10.2165/11532980-000000000-00000. Review.

PMID:
20690781
5.

Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.

Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA.

Eur J Clin Pharmacol. 2013 Jul;69(7):1401-9. doi: 10.1007/s00228-013-1475-y. Epub 2013 Feb 14.

6.
7.

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.

J Am Heart Assoc. 2013 Jan 28;2(1):e003277. doi: 10.1161/JAHA.112.003277.

8.

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1265-76. doi: 10.1517/17425255.2010.513699. Review.

PMID:
20707611
9.

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM.

Clin Drug Investig. 2010;30(12):855-66. doi: 10.2165/11538410-000000000-00000.

PMID:
20923244
10.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
11.

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ.

Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. Review.

PMID:
20590741
12.

Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.

Bhome R, Penn H.

Diabet Med. 2012 May;29(5):693-4. doi: 10.1111/j.1464-5491.2011.03502.x. No abstract available.

PMID:
22023482
13.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.

14.

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR.

Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Review.

PMID:
20629618
15.

The effects of simvastatin on the pharmacokinectics of sitagliptin.

Cerra M, Luo WL, Li SX, Matthews C, O'Neill EA, Wagner JA, Stoch SA, Anderson MS.

J Popul Ther Clin Pharmacol. 2012;19(3):e356-60. Epub 2012 Oct 11.

16.

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Chwieduk CM.

Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Review.

PMID:
21319871
17.

New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

Green J, Feinglos M.

Vasc Health Risk Manag. 2008;4(4):743-51. Review.

18.

Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.

Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:88-102. doi: 10.1111/j.1447-0594.2011.00816.x.

PMID:
22435944
19.

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.

McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study.

Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12.

PMID:
20487050
20.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk